成人免费xx,国产又黄又湿又刺激不卡网站,成人性视频app菠萝网站,色天天天天

Home Cart Sign in  
HazMat Fee +

There will be a HazMat fee per item when shipping a dangerous goods. The HazMat fee will be charged to your UPS/DHL/FedEx collect account or added to the invoice unless the package is shipped via Ground service. Ship by air in Excepted Quantity (each bottle), which is up to 1g/1mL for class 6.1 packing group I or II, and up to 25g/25ml for all other HazMat items.

Type HazMat fee for 500 gram (Estimated)
Excepted Quantity USD 0.00
Limited Quantity USD 15-60
Inaccessible (Haz class 6.1), Domestic USD 80+
Inaccessible (Haz class 6.1), International USD 150+
Accessible (Haz class 3, 4, 5 or 8), Domestic USD 100+
Accessible (Haz class 3, 4, 5 or 8), International USD 200+
Chemical Structure| 137071-32-0 Chemical Structure| 137071-32-0
Chemical Structure| 137071-32-0

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

{[proInfo.proName]}

CAS No.: 137071-32-0

,{[proInfo.pro_purity]}

Pimecrolimus is an immunomodulating agent of the calcineurin inhibitor class， effective in various inflammatory skin diseases, including seborrheic dermatitis, cutaneous lupus erythematosus, oral lichen planus, vitiligo and psoriasis.

Synonyms: SDZ-ASM 981; Elidel; Rizan

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support Online Technical Q&A
Product Citations

Alternative Products

Product Details of Pimecrolimus

CAS No. :137071-32-0
Formula : C43H68ClNO11
M.W : 810.45
SMILES Code : O=C([C@@](CCCC1)([H])N1C(C([C@@]2(O)[C@H](C)C[C@H](OC)[C@@](O2)([H])[C@@H](OC)C[C@@H](C)C/C(C)=C/[C@H]3CC)=O)=O)O[C@H](/C(C)=C/[C@H]4C[C@@H](OC)[C@@H](Cl)CC4)[C@H](C)[C@@H](O)CC3=O
Synonyms :
SDZ-ASM 981; Elidel; Rizan

Safety of Pimecrolimus

GHS Pictogram:
Signal Word:Danger
Hazard Statements:H301
Precautionary Statements:P264-P270-P301+P310+P330-P405-P501
Class:6.1
UN#:2811
Packing Group:Ⅲ

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description Reference
Vero cells 20 μM 12 hours To evaluate the inhibitory effect of pimecrolimus on DENV2 infection, results showed pimecrolimus significantly inhibited DENV2 replication PMC11164929
CD1a+ Langerhans cells in human foreskin tissues 1% cream 18 hours, 24 hours, 48 hours To investigate the effect of Pimecrolimus on high-dose UVB irradiation-induced epidermal Langerhans cell migration. Results showed that Pimecrolimus inhibited UVB-induced Langerhans cell migration. PMC4199986
Normal human epidermal keratinocytes (NHEKs) 10 nM 24 hours Pimecrolimus enhanced the expression of antimicrobial peptides (e.g., cathelicidin, HBD2, and HBD3) induced by TLR2/6 ligand Malp-2 and increased the antimicrobial activity of keratinocytes against Staphylococcus aureus. PMC2639780
BHK-21 cells 20 μM 48 hours To evaluate the inhibitory effect of pimecrolimus on DENV2 infection, results showed pimecrolimus significantly inhibited DENV2 replication PMC11164929
CD4+ T cells 0.55 nM (IC50) 5 days Inhibited T cell proliferation with an IC50 of 0.55 nM PMC1906497
CD4+ T cells 0.1 nM, 1 nM, 10 nM 5 days Inhibited the expression of CD134, CD25, and CD54, pimecrolimus was 10-fold more potent than CyA PMC1906497
Human monocyte-derived dendritic cells 1 nM to 100 nM 6 days To compare the effects of Pimecrolimus with corticosteroids (Dex and b-MSV) on dendritic cell differentiation and function. Results showed that Pimecrolimus did not affect dendritic cell differentiation, maturation, and function, whereas corticosteroids significantly inhibited these processes. PMC1808796
Human umbilical cord blood mesenchymal stem cells (hUCB-MSCs) 0.01 ng/ml, 1 ng/ml, 100 ng/ml 72 hours To investigate the effect of Pimecrolimus on PGE2 production in hUCB-MSCs. Results showed that Pimecrolimus reduced the secretion of PGE2 in a dose-dependent manner. PMC8399851
Huh-7 cells 20 μM 72 hours To evaluate the inhibitory effect of pimecrolimus on DENV2 infection, results showed pimecrolimus significantly inhibited DENV2 replication PMC11164929

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description Reference
NC/Nga mice Df-induced AD model Topical application 0.2 g/head Once daily for 7 days To investigate the therapeutic effect of Pimecrolimus combined with hUCB-MSCs in AD mouse model. Results showed that Pimecrolimus disturbed the therapeutic effect of hUCB-MSCs. PMC8399851
IFNAR1-knockout mice DENV2 infection model Oral 15 and 30 mg/kg Twice daily for 14 days To evaluate the inhibitory effect of pimecrolimus on DENV2 infection, results showed pimecrolimus significantly alleviated body weight loss and lethality, and reduced viral load PMC11164929

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT00377962 Disorder Related to Cardiac Tr... More >>ansplantation Less << Phase 4 Completed - Denmark ... More >> Novartis Investigative Site Arhus, Denmark, DK-8200 Novartis Investigative Site Copenhagen, Denmark, 2100 Norway Novartis Investigative Site Oslo, Norway Sweden Novartis Investigative Site Goteborg, Sweden, 413 45 Novartis Investigative Site Linkoping, Sweden, 581 85 Novartis Investigative Site Lund, Sweden, 22185 Less <<
NCT00377962 - Completed - -
NCT00148746 Moderate to Severe Atopic Derm... More >>atitis Less << Not Applicable Completed - Germany ... More >> Department of Dermatology, TU Dresden Dresden, Germany, 01307 Less <<
NCT02421770 Oral Lichen Planus Phase 3 Completed - Spain ... More >> Pia Lopez Jornet Murcia, Spain, 30008 Less <<
NCT02376049 Atopic Dermatitis Phase 1 Completed - Canada, Quebec ... More >> Innovaderm Research Inc. Montreal, Quebec, Canada, H2K 4L5 Israel Beit Harofim Netanya, Israel, 42701 Less <<
NCT02103725 Atopic Dermatitis Phase 1 Completed - Germany ... More >> bioskin GmbH Hamburg, Germany, 20095 Less <<
NCT03142139 - Completed - -
NCT03539601 Atopic Dermatitis Phase 4 Recruiting May 25, 2020 United States, Arkansas ... More >> Dermatology Trial Associates Recruiting Bryant, Arkansas, United States, 72022 United States, California California Dermatology & Clinical Research Institute Recruiting Encinitas, California, United States, 92024 United States, Florida Park Avenue Dermatology Recruiting Orange Park, Florida, United States, 32073 Forward Clinical Trials, Inc. Recruiting Tampa, Florida, United States, 33624 United States, Kentucky DS Research Recruiting Louisville, Kentucky, United States, 40241 United States, North Carolina M3-Wake Research, Inc. Recruiting Raleigh, North Carolina, United States, 27612 United States, Texas Arlington Research Center Inc Recruiting Arlington, Texas, United States, 76011 United States, Virginia Virginia Clinical Research, Inc Recruiting Norfolk, Virginia, United States, 23502 Less <<
NCT01082393 Vitiligo Phase 4 Unknown December 2015 Belgium ... More >> University Hospital Ghent Recruiting Ghent, Belgium Principal Investigator: Nanny Van Geel, MD, PhD Less <<
NCT00969397 Port Wine Stain Phase 1 Phase 2 Withdrawn(We have decided not ... More >>to pursue the study) Less << - -
NCT02583022 Atopic Dermatitis Phase 2 Completed - -
NCT01037881 Atopic Dermatitis Phase 2 Completed - Canada, Ontario ... More >> Windsor Clinical Research Inc. Windsor, Ontario, Canada, N8W 5L7 Finland Helsinki University Central Hospital Helsinki, Finland, 00250 Germany Klinik und Poliklinik für Dermatologie, Universit?t Bonn Bonn, Germany, 53105 Less <<
NCT00568412 Mild to Moderate Atopic Dermat... More >>itis Less << Phase 4 Completed - Germany ... More >> Klinik und Poliklinik fuer Dermatologie, Universtitaetsklinikum Bonn, Germany, 53105 Less <<
NCT00379678 - Completed - United States, Colorado ... More >> National Jewish Medical and Research Center Denver, Colorado, United States, 80206 Less <<
NCT00098150 - Completed - -
NCT00180141 Atopic Dermatitis Phase 4 Completed - Germany ... More >> Technical University Dresden Dresden, Sachsen, Germany, 01307 Less <<
NCT00460083 Atopic Dermatitis Phase 4 Completed - United States, California ... More >> UCSD San Diego, California, United States United States, Oregon OHSU Portland, Oregon, United States Less <<
NCT00403559 Seborrheic Dermatitis Phase 2 Completed - United States, Kentucky ... More >> Dermatology Specialists Louisville, Kentucky, United States, 40202 Less <<
NCT00150059 Atopic Dermatitis Phase 4 Completed - Philippines ... More >> This study is not being conducted in the United States Investigative Site, Philippines Less <<
NCT00322569 Coronary Disease Phase 3 Completed - United Kingdom ... More >> Southampton University Hospital Southampton, United Kingdom, SO16 YD Less <<
NCT00655512 Healthy Phase 1 Completed - Germany ... More >> Department of Dermatology, Medical Faculty, TU Dresden Dresden, Germany Less <<
NCT00130572 Lichen Planus, Oral PHASE3 COMPLETED 2025-12-07 University Hospital, Departmen... More >>t of Dermatology, Tuebingen, 72076, Germany Less <<
NCT00119158 Atopic Dermatitis Phase 4 Completed - United States, Colorado ... More >> National Jewish Research Medical Center Denver, Colorado, United States, 80206 United States, Illinois Northwestern University School of Medicine Chicago, Illinois, United States, 60611 United States, Texas University of Texas at Houston Medical School Houston, Texas, United States, 77030 Less <<
NCT00222183 Lupus Erythematosus, Cutaneous... More >> Lupus Erythematosus, Discoid Less << Not Applicable Withdrawn(Head of the study ha... More >>s left the institution. Study never started.) Less << - Germany ... More >> Department of Dermatology, University of Leipzig Leipzig, Saxony, Germany, 04103 Less <<
NCT00372307 Vitiligo Vulgaris Phase 2 Completed - Belgium ... More >> University Hospital Ghent Ghent, Belgium, 9000 Less <<
NCT00098189 - Completed - -
NCT00393263 Lichen Sclerosus Phase 2 Completed - United States, District of Col... More >>umbia Center for VulvoVaginal Disorders Washington, District of Columbia, United States, 21012 Less <<
NCT00666159 Dermatitis, Atopic Phase 4 Completed - United States, Connecticut ... More >> New Haven, Connecticut, United States, 06519 United States, Florida Miami, Florida, United States, 33136 Miami, Florida, United States, 33155 United States, Illinois Chicago, Illinois, United States, 60614 United States, Massachusetts Boston, Massachusetts, United States, 02115 United States, Michigan Clinton Township, Michigan, United States, 48038 United States, Nebraska Omaha, Nebraska, United States, 68144 United States, Nevada Reno, Nevada, United States, 89511 United States, North Carolina Chapel Hill, North Carolina, United States, 27599 Wilmington, North Carolina, United States, 28401 Winston Salem, North Carolina, United States, 27157 United States, Texas Houston, Texas, United States, 77030 Less <<
NCT00667160 Dermatitis, Atopic Phase 4 Completed - United States, California ... More >> San Diego, California, United States, 92123 United States, Connecticut New Haven, Connecticut, United States, 06519 United States, Florida Miami, Florida, United States, 33136 Miami, Florida, United States, 33155 United States, Illinois Chicago, Illinois, United States, 60614 United States, Massachusetts Boston, Massachusetts, United States, 02115 United States, Michigan Clinton township, Michigan, United States, 48308 United States, Minnesota Fridley, Minnesota, United States, 55432 United States, Nebraska Omaha, Nebraska, United States, 68144 United States, Nevada Reno, Nevada, United States, 89511 United States, North Carolina Durham, North Carolina, United States, 27705 Wilmington, North Carolina, United States, 28401 Winston Salem, North Carolina, United States, 27157 United States, Ohio Cleveland, Ohio, United States, 44106 United States, Oregon Portland, Oregon, United States, 97201 United States, Pennsylvania Pittsburgh, Pennsylvania, United States, 15218 United States, Texas Dallas, Texas, United States, 75390 Galveston, Texas, United States, 77555 Houston, Texas, United States, 62016 Less <<
NCT02443311 Oral Lichen Planus Phase 4 Completed - -
NCT00120302 Atopic Dermatitis Phase 4 Completed - United Kingdom ... More >> This study is not being conducted in the United States Novartis Pharmaceuticals UK, Frimley, United Kingdom Less <<
NCT00610142 Atopic Dermatitis Phase 2 Completed - Germany ... More >> Department of Dermatology, Medical Faculty, TU Dresden Dresden, Germany Less <<
NCT03107611 Atopic Dermatitis Phase 3 Completed - -
NCT00666302 Dermatitis, Atopic Phase 4 Completed - United States, Alabama ... More >> Birmingham, Alabama, United States, 35205 United States, California San Francisco, California, United States, 94118 United States, Kansas Kansas City, Kansas, United States, 66160 United States, Michigan Ann Arbor, Michigan, United States, 48109 United States, Missouri St Louis, Missouri, United States, 63110 United States, New York New York, New York, United States, 10029 United States, North Carolina Winston-Salem, North Carolina, United States, 27157 United States, Ohio Cincinnati, Ohio, United States, 45219 United States, Pennsylvania Philadelphia, Pennsylvania, United States, 19107 United States, Texas Dallas, Texas, United States, 75230 San Antonio, Texas, United States, 78229 United States, Utah Salt Lake City, Utah, United States, 84124 United States, Virginia Norfolk, Virginia, United States, 23507 Canada, Nova Scotia Halifax, Nova Scotia, Canada, B3H 1V7 Halifax, Nova Scotia, Canada, B3H 1Z4 Less <<
NCT00119158 - Completed - -
NCT01524744 Oral Lichen Planus Phase 2 Unknown December 2012 Iran, Islamic Republic of ... More >> Mashhad University of Medical Science Mashhad, Khorasan Razavi, Iran, Islamic Republic of, 91735 Less <<
NCT03297502 Atopic Dermatitis Phase 3 Completed - -
NCT00507832 Prurigo Nodularis Phase 2 Completed - Germany ... More >> Department of Dermtology, University of Münster Münster, Germany, 48149 Less <<
NCT00484003 Atopic Eczema Phase 4 Completed - South Africa ... More >> Investigative Sites Various Cities, South Africa Less <<
NCT00321750 Oral Erosive Lichen Planus Phase 2 Terminated - -
NCT00128245 Keratoconjunctivitis Sicca Not Applicable Completed - United States, New Jersey ... More >> Novartis East Hanover, New Jersey, United States Less <<
NCT02896101 Atopic Dermatitis Phase 3 Completed - United States, Arkansas ... More >> Investigational Site 4 Hot Springs, Arkansas, United States Investigational Site 22 Little Rock, Arkansas, United States United States, California Investigational Site 20 Anaheim, California, United States Investigational Site 13 Fremont, California, United States Investigational Site 26 Norco, California, United States United States, Florida Investigational Site 17 Doral, Florida, United States Investigational Site 9 Hialeah, Florida, United States Investigational Site 16 Miami, Florida, United States Investigational Site 18 Miami, Florida, United States Investigational Site 19 Miami, Florida, United States Investigational Site 25 Miami, Florida, United States Investigational Site 8 Miami, Florida, United States Investigational Site 12 North Miami Beach, Florida, United States Investigational Site 3 Ormond Beach, Florida, United States Investigational Site 7 South Miami, Florida, United States Investigational Site 10 Tampa, Florida, United States Investigational Site 24 Tampa, Florida, United States Investigational Site 14 West Palm Beach, Florida, United States United States, Illinois Investigational Site 1 Arlington Heights, Illinois, United States United States, Louisiana Investigational Site 21 Lake Charles, Louisiana, United States United States, Maryland Investigational Site 2 Silver Spring, Maryland, United States United States, Missouri Investigational Site 11 Saint Joseph, Missouri, United States United States, New Jersey Investigational Site 27 East Windsor, New Jersey, United States United States, North Carolina Investigational Site 5 High Point, North Carolina, United States Investigational Site 23 Raleigh, North Carolina, United States United States, Ohio Investigational Site 15 Cincinnati, Ohio, United States United States, Tennessee Investigational Site 6 Nashville, Tennessee, United States Less <<
NCT00232011 Atopic Dermatitis Phase 3 Completed - Japan ... More >> This study is not being conducted in the United States Various Cities, Japan Less <<
NCT00608673 Discoid Lupus Erythematosus Not Applicable Completed - Iran, Islamic Republic of ... More >> Shohada'e Tajrish Hospital Tehran, Iran, Islamic Republic of, 1989934148 Less <<
NCT00322543 Coronary Disease Phase 3 Terminated - Brazil ... More >> Institute Dante Pazzanese of Cardiology Sao Paulo, SP, Brazil, 04012-180 Less <<
NCT00124709 Atopic Dermatitis Phase 4 Terminated - -
NCT00130364 Atopic Dermatitis Phase 4 Completed - United States, New Jersey ... More >> This study is not being conducted in the United States Novartis Pharmaceuticals, New Jersey, United States Less <<
NCT00124709 - Terminated - -
NCT00121316 Atopic Dermatitis Phase 4 Completed - Switzerland ... More >> This study is not being conducted in the United States Novartis Pharma AG, Switzerland Less <<
NCT00810862 Atopic Dermatitis Phase 4 Terminated(Lack of subject enr... More >>ollment over the past two years.) Less << - -
NCT00226707 Chronic Hand Dermatitis Phase 3 Completed - -
NCT01177566 Atopic Dermatitis Phase 4 Completed - United States, New York ... More >> Mount Sinai School of Medicine Department of Dermatology Clinical Trials New York, New York, United States, 10029 Less <<
NCT00120523 - Completed - -
NCT00208026 Netherton Syndrome Phase 1 Phase 2 Completed - United States, Pennsylvania ... More >> Children's Hospital of Philadelphia Philadelphia, Pennsylvania, United States, 19104 Less <<
NCT00121381 Dermatitis, Atopic Phase 4 Completed - United States, California ... More >> Pediatric Care Medical Group, Inc. Huntington Beach, California, United States, 92647 Children's Hospital -San Diego San Diego, California, United States, 92123 United States, Colorado National Jewish Medical and Research Center Denver, Colorado, United States, 80206 United States, Florida Dermatology Associates and Research Coral Gables, Florida, United States, 33134 United States, Georgia Medical College of Georgia - Clinical Investigative Services Augusta, Georgia, United States, 30912 United States, New Hampshire Dartmouth Hitchcock Medical Center Section of Dermatology Lebanon, New Hampshire, United States, 03756 United States, North Carolina Wake Forest University School of Medicine Dept. of Dermatology Winston-Salem, North Carolina, United States, 27157 United States, Oregon Calcagno Research and Development Gresham, Oregon, United States, 97030 United States, Pennsylvania Children's Hospital of Philadelphia Philadelphia, Pennsylvania, United States, 19104 United States, Rhode Island Rhode Island Hospital Providence, Rhode Island, United States, 02903 United States, Tennessee 520 Trinity Creek Cove Cordova, Tennessee, United States, 38018 United States, Virginia Virginia Commonwealth University Richmond, Virginia, United States, 23298 United States, Washington A.S.T.H.M.A., Inc Seattle, Washington, United States, 98105 Less <<
NCT00231998 Atopic Dermatitis PHASE3 COMPLETED 2025-06-05 This study is not being conduc... More >>ted in the United States, Various Cities, Japan Less <<
NCT00208026 - Completed - -
NCT00232115 Perioral Dermatitis Phase 3 Completed - Germany ... More >> Novartis Pharmaceuticals Nürnberg, Germany Less <<
NCT00139581 Atopic Dermatitis Phase 4 Completed - Switzerland ... More >> This study is not being conducted in the United States Novartis Pharma AG, Basel, Switzerland Less <<
NCT00297037 Oral Lichen Planus Phase 2 Completed - United States, Utah ... More >> University of Utah Salt Lake City, Utah, United States, 84132 Less <<
NCT00297037 - Completed - -
NCT00120523 Atopic Dermatitis Phase 3 Completed - -
NCT01202149 Eczema Atopic... More >> Dermatitis Less << Phase 4 Completed - United States, New York ... More >> Mount Sinai Faculty Practice Associates New York, New York, United States, 10029 Less <<
NCT00367393 Atopic Dermatitis Phase 4 Completed - Germany ... More >> Novartis Novartis, Germany Less <<
NCT01132079 Atopic Dermatitis Not Applicable Completed - Germany ... More >> Dept. of Dermatology, University of Kiel Kiel, Germany, 24105 Less <<
NCT00946478 Atopic Dermatitis Not Applicable Completed - United States, California ... More >> University of California, San Diego - Dept of Dermatology La Jolla, California, United States, 92037 Less <<
NCT02791308 Atopic Dermatitis Phase 3 Completed - -
NCT00351052 Atopic Dermatitis Phase 3 Completed - Germany ... More >> Investigational Site, Germany Less <<
NCT00509990 Atopic Dermatitis PHASE4 COMPLETED - Novartis Investigative Site, M... More >>exico, Mexico|Novartis Investigative Site, Monterrey, Mexico|Novartis Investigative Site, Puebla, Mexico|Novartis Investigative Site, Aragua, Venezuela|Novartis Investigative Site, Edo, Carabobo, Venezuela|Novartis Investigative Site, Caracas, Venezuela Less <<
NCT00510003 Atopic Dermatitis PHASE4 COMPLETED - Novartis Investigative Site, M... More >>adrid, Spain Less <<
NCT00117377 Atopic Dermatitis Phase 4 Completed - United States, New York ... More >> Mount Sinai School of Medicine New York, New York, United States New York University Hospital New York, New York, United States United States, Virginia Virginia Clinical Research, Inc Norfolk, Virginia, United States Less <<
NCT00925730 Atopic Dermatitis PHASE4 COMPLETED - Novartis Investigative Site, B... More >>onn, Germany|Novartis Investigative Site, Frankfurt am Main, Germany Less <<
NCT01692626 - Terminated(Interim analysis sh... More >>ows no efficacy) Less << - -
NCT01692626 Rash Phase 2 Terminated(Interim analysis sh... More >>ows no efficacy) Less << - United States, West Virginia ... More >> West Virginia University Hospitals Mary Babb Randolph Cancer Center Morgantown, West Virginia, United States, 26506 Less <<
NCT00946478 - Completed - -
NCT00568997 Atopic Dermatitis RECRUITING 2025-12-26 Registry, Philadelphia, Pennsy... More >>lvania, 19104, United States Less <<

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

1.23mL

0.25mL

0.12mL

6.17mL

1.23mL

0.62mL

12.34mL

2.47mL

1.23mL
Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories